Vor Bio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Vor Bio (VOR) to Buy from Neutral with a $3 price target Vor’s board has strategically strengthened the “three pillars” needed to potentially increase the odds to become a commercial company in 24-30 months from now, the analyst tells investors. The firm is “encouraged by the quick resurrection of the company by the board and the management” after the company entered into an exclusive license agreement with RemeGen Co. to develop and commercialize telitacicept, the analyst added.